dcsimg
For Healthcare ProfessionalsIntended for US Audiences

Personalized dosing for your patients while maintaining efficacy1

Every-second-day and every-third-day dosing options with ADVATE [Antihemophilic Factor (Recombinant)] prophylaxis were both shown to be effective in a clinical trial.1

Analysis of the 2 prophylaxis dosing regimens showed that the median doses used for standard every-second-day prophylaxis and every-third-day prophylaxis were 31.4 IU/kg and 43.0 IU/kg, respectively. Throughout the prophylaxis period, target FVIII levels were maintained: median (range) trough levels were 3.0 (0.5-45.0) IU dL-1 during standard prophylaxis (56 observations in 24 subjects) and 1.0 (0.5-10.0) during PK-tailored prophylaxis (52 observations in 23 subjects).4

Every-second-day and every-third-day prophylaxis

This is an example intended only to illustrate dosing options and is not intended to be used to calculate dosing for the treatment of a patient.*

Dosing Options for ADVATE [Antihemophilic Factor (Recombinant)]: Every-second-day and every-third-day prophylaxis.
Every-second-day and every-third-day prophylaxis were targeted to maintain FVIII trough levels ≤1%.4

*This example assumes that the patient’s initial factor VIII level was 0. The expected in vivo peak increase in factor VIII level expressed as IU/dL of plasma or percent normal has been estimated by multiplying the dose administered per kg body weight (IU/kg) by 2.1